» Articles » PMID: 30866507

In Silico Methods for the Discovery of Orthosteric GABA Receptor Compounds

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2019 Mar 15
PMID 30866507
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The GABA receptor (GABA-R) is a heterodimeric class C G protein-coupled receptor comprised of the GABA and GABA subunits. The endogenous orthosteric agonist γ-amino-butyric acid (GABA) binds within the extracellular Venus flytrap (VFT) domain of the GABA subunit. The receptor is associated with numerous neurological and neuropsychiatric disorders including learning and memory deficits, depression and anxiety, addiction and epilepsy, and is an interesting target for new drug development. Ligand- and structure-based virtual screening (VS) are used to identify hits in preclinical drug discovery. In the present study, we have evaluated classical ligand-based in silico methods, fingerprinting and pharmacophore mapping and structure-based in silico methods, structure-based pharmacophores, docking and scoring, and linear interaction approximation (LIA) for their aptitude to identify orthosteric GABA-R compounds. Our results show that the limited number of active compounds and their high structural similarity complicate the use of ligand-based methods. However, by combining ligand-based methods with different structure-based methods active compounds were identified in front of DUDE-E decoys and the number of false positives was reduced, indicating that novel orthosteric GABA-R compounds may be identified by a combination of ligand-based and structure-based in silico methods.

Citing Articles

Mind the Gap-Deciphering GPCR Pharmacology Using 3D Pharmacophores and Artificial Intelligence.

Noonan T, Denzinger K, Talagayev V, Chen Y, Puls K, Wolf C Pharmaceuticals (Basel). 2022; 15(11).

PMID: 36355476 PMC: 9695541. DOI: 10.3390/ph15111304.


Interrogation of SrtA active site loop forming open/close lid conformations through extensive MD simulations for understanding binding selectivity of SrtA inhibitors.

Selvaraj C, Selvaraj G, Mohamed Ismail R, Vijayakumar R, Baazeem A, Wei D Saudi J Biol Sci. 2021; 28(7):3650-3659.

PMID: 34220215 PMC: 8241892. DOI: 10.1016/j.sjbs.2021.05.009.


Computational Screening of Potential Inhibitors of for Pyrite Scale Prevention in Oil and Gas Wells.

Onawole A, Hussein I, Saad M, Ahmed M, Nimir H ACS Omega. 2021; 6(16):10607-10617.

PMID: 34056214 PMC: 8153761. DOI: 10.1021/acsomega.0c06078.


The GABA Receptor-Structure, Ligand Binding and Drug Development.

Evenseth L, Gabrielsen M, Sylte I Molecules. 2020; 25(13).

PMID: 32646032 PMC: 7411975. DOI: 10.3390/molecules25133093.

References
1.
Froestl W, Mickel S, von Sprecher G, Diel P, Hall R, Maier L . Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. J Med Chem. 1995; 38(17):3313-31. DOI: 10.1021/jm00017a016. View

2.
Kaupmann K, Huggel K, Heid J, Flor P, Bischoff S, Mickel S . Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997; 386(6622):239-46. DOI: 10.1038/386239a0. View

3.
Calver A, Medhurst A, Robbins M, Charles K, Evans M, Harrison D . The expression of GABA(B1) and GABA(B2) receptor subunits in the cNS differs from that in peripheral tissues. Neuroscience. 2000; 100(1):155-70. DOI: 10.1016/s0306-4522(00)00262-1. View

4.
Cryan J, Slattery D . GABAB receptors and depression. Current status. Adv Pharmacol. 2010; 58:427-51. DOI: 10.1016/S1054-3589(10)58016-5. View

5.
Varani A, Aso E, Moutinho L, Maldonado R, Balerio G . Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations. Psychopharmacology (Berl). 2014; 231(15):3031-40. DOI: 10.1007/s00213-014-3469-6. View